Similar articles

• False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.

  Reinsberg J, Wagner U, Krebs D. Reinsberg J, et al. Arch Gynecol Obstet. 1994;255(1):9-18. doi: 10.1007/BF02390669. Arch Gynecol Obstet. 1994. PMID: 8042882
• Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.

  Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G. Baum RP, et al. Hybridoma. 1993 Oct;12(5):583-9. doi: 10.1089/hyb.1993.12.583. Hybridoma. 1993. PMID: 8300134 No abstract available.
• Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.

  Sakahara H, Saga T, Onodera H, Yao Z, Nakamoto Y, Zhang M, Sato N, Nakada H, Yamashina I, Endo K, Konishi J. Sakahara H, et al. Jpn J Cancer Res. 1997 Sep;88(9):895-9. doi: 10.1111/j.1349-7006.1997.tb00466.x. Jpn J Cancer Res. 1997. PMID: 9369938 Free PMC article.
• Immunodiagnosis of ovarian tumors.

  Jacobs I, Bast RC Jr. Jacobs I, et al. Immunol Ser. 1990;53:323-38. Immunol Ser. 1990. PMID: 2100566 Review. No abstract available.
• The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma.

  Bast RC Jr, Knapp RC. Bast RC Jr, et al. Important Adv Oncol. 1987:39-53. Important Adv Oncol. 1987. PMID: 3331386 Review. No abstract available.